DE69941344D1 - Spezifische Antikörper enthaltende Bindungsproteine die das nekrotische Tumorzentrum binden und deren Verwendung - Google Patents

Spezifische Antikörper enthaltende Bindungsproteine die das nekrotische Tumorzentrum binden und deren Verwendung

Info

Publication number
DE69941344D1
DE69941344D1 DE69941344T DE69941344T DE69941344D1 DE 69941344 D1 DE69941344 D1 DE 69941344D1 DE 69941344 T DE69941344 T DE 69941344T DE 69941344 T DE69941344 T DE 69941344T DE 69941344 D1 DE69941344 D1 DE 69941344D1
Authority
DE
Germany
Prior art keywords
bind
binding proteins
specific antibody
containing binding
necrotic tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941344T
Other languages
English (en)
Inventor
Andrew James Williams
Philip Ronald Tempest
Thor Las Holtet
Helen Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avid Bioservices Inc
Original Assignee
Peregrine Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peregrine Pharmaceuticals Inc filed Critical Peregrine Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69941344D1 publication Critical patent/DE69941344D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69941344T 1998-07-02 1999-07-02 Spezifische Antikörper enthaltende Bindungsproteine die das nekrotische Tumorzentrum binden und deren Verwendung Expired - Lifetime DE69941344D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9814383.7A GB9814383D0 (en) 1998-07-02 1998-07-02 Improvements relating to antibodies

Publications (1)

Publication Number Publication Date
DE69941344D1 true DE69941344D1 (de) 2009-10-08

Family

ID=10834856

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69927268T Expired - Lifetime DE69927268T2 (de) 1998-07-02 1999-07-02 Spezifische antikörper enthaltende bindungsproteine die das nekrotische tumorzentrum binden und deren verwendung
DE69941344T Expired - Lifetime DE69941344D1 (de) 1998-07-02 1999-07-02 Spezifische Antikörper enthaltende Bindungsproteine die das nekrotische Tumorzentrum binden und deren Verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69927268T Expired - Lifetime DE69927268T2 (de) 1998-07-02 1999-07-02 Spezifische antikörper enthaltende bindungsproteine die das nekrotische tumorzentrum binden und deren verwendung

Country Status (9)

Country Link
US (2) US6827925B1 (de)
EP (2) EP1092028B1 (de)
JP (1) JP4544744B2 (de)
AU (1) AU766564C (de)
CA (1) CA2336114C (de)
DE (2) DE69927268T2 (de)
GB (1) GB9814383D0 (de)
HK (1) HK1086598A1 (de)
WO (1) WO2000001822A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US8795672B2 (en) 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
EP2366717A3 (de) 2004-10-29 2011-12-14 University of Southern California Kombination aus Krebs- und Immuntherapie mit costimulatorischen Molekülen
US20060135459A1 (en) * 2004-11-09 2006-06-22 Epstein Alan L Targeted innate immunity
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
CN101528259B (zh) 2006-10-02 2014-04-09 梅达雷克斯有限责任公司 结合cxcr4的人类抗体及其用途
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2011206049A (ja) 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107922484A (zh) * 2015-03-06 2018-04-17 索伦托治疗有限公司 结合tim3的抗体治疗剂
EP3288568A4 (de) * 2015-04-30 2019-01-02 University of Southern California Sekretorische tnt-car-zellimmuntherapie
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
KR20210040827A (ko) 2018-07-25 2021-04-14 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항 tigit 항체 및 그 용도
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
BR112022017174A2 (pt) 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
KR20230010691A (ko) 2020-05-12 2023-01-19 치아타이 티안큉 파마수티컬 그룹 주식회사 St2 항원 결합 단백질

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US20020193571A1 (en) * 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies

Also Published As

Publication number Publication date
EP1092028B1 (de) 2005-09-14
CA2336114A1 (en) 2000-01-13
JP4544744B2 (ja) 2010-09-15
EP1092028A1 (de) 2001-04-18
EP1621622B1 (de) 2009-08-26
EP1621622A1 (de) 2006-02-01
JP2002519065A (ja) 2002-07-02
AU766564C (en) 2004-11-04
GB9814383D0 (en) 1998-09-02
WO2000001822A1 (en) 2000-01-13
DE69927268D1 (de) 2005-10-20
AU766564B2 (en) 2003-10-16
HK1086598A1 (en) 2006-09-22
US6827925B1 (en) 2004-12-07
AU4634399A (en) 2000-01-24
CA2336114C (en) 2010-10-12
US20050054007A1 (en) 2005-03-10
DE69927268T2 (de) 2006-06-22
US7605234B2 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
DE69941344D1 (de) Spezifische Antikörper enthaltende Bindungsproteine die das nekrotische Tumorzentrum binden und deren Verwendung
ID22588A (id) Zat pengikat untuk bahan fungsional blok padatan
ATE402191T1 (de) Rekombinante il-18 antikörper und deren verwendung
CY2005011I1 (el) ΑΝΘΡΩΠΙΝΑ ΑΝΤΙΣΩΜΑΤΑ ΤΑ ΟΠΟΙΑ ΔΕΣΜΕΥΟΥΝ ΤΟΝ ΑΝΘΡΩΠΙΝΟ TNFα
ATE451460T1 (de) Antikörpermoleküle mit spezifizität für menschlichen tumornekrosefaktor-alpha, und deren verwendung
NO20002546D0 (no) Flerkomponent, superabsorberende gelpartikler
DE59805031D1 (de) Verwendungen anionenaustauschender mineralien, die no3- reversibel binden
DE19880515T1 (de) Lockenstab
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
DE69937344D1 (de) Faktoren die das tumor necrosis faktor rezeptor abspaltende enzym beeinflussen
DE69729449D1 (de) Rekombinante alpha-2,3-sialyltransferasen und deren verwendung
DE69504085D1 (de) Nagellack mit mikrogelpartikeln
NO971448D0 (no) Anti-Fas rekombinante antistoffer og DNA derfor
DE69705017D1 (de) Medikamente bindendes Protein
BR9506270A (pt) Receptor de elicitador de glucano e molécula de dna codificado para o mesmo
DE69533439D1 (de) Thymidinkinase tk1, peptide, die korrespondierenden antikörper und ihre verwendung zur bestimmung der tumorproliferation
DE69811651D1 (de) Enthaarungszusammensetzungen, die bereitung und die verwendung derselben
DE69800080T2 (de) Antikörper gegen das Prorenin Profragment, reninaktive Substanz die diese enthält und Prorenintest die diese verwendet
DE69532881D1 (de) Ecdn - protein und dafuer kodeierende dna
DE69705097T2 (de) Radiografische Elemente mit ultradünnen Tafelkorn-Emulsionen
DE69519715D1 (de) PRLTS-Proteine und die dafür kodierende DNA
DE29723433U1 (de) 3-Wege-Mischer
DE29714086U1 (de) Wendelrutsche
ATE290074T1 (de) Monoklonaler antikörper gegen humanes mp52
KR970060724U (ko) 차량용 방향기

Legal Events

Date Code Title Description
8364 No opposition during term of opposition